Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology
Initiation of the Phase 1 clinical expansion trial triggers a €10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics. The trial is being conducted in advanced hepatocellular
Source: finanznachrichten.de
